原始细胞危象

O'Brien S, Berman E, Bhalla K, et al; National Comprehensive Cancer Network. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007;5:474-496.

• 摘要

Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007:371-375.

• 全文
• 摘要

Breccia M, Salaroli A, Molica M, et al. Systematic review of dasatinib in chronic myeloid leukemia. Onco Targets Ther. 2013;6:257-265.

• 全文
• 摘要

Shamroe CL, Comeau JM. Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother. 2013;47:1540-1546.

• 摘要

Stansfield L, Hughes TE, Walsh-Chocolaad TL. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia. Ann Pharmacother. 2013;47:1703-1711.

• 摘要

Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA. 2005;102:11011-11016.

• 全文
• 摘要

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93.

• 全文
• 摘要

1.  Ghelani D, Sneed TB, Bueso-Ramos CE, et al. Chapter 4. Chronic myeloid leukemia. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson manual of medical oncology. New York, NY: McGraw-Hill; 2006:57-74.

2.  Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.

• 全文
• 摘要

3.  Corso A, Lazzarino M, Morra E, et al. Chronic myelogenous leukemia and exposure to ionizing radiation - a retrospective study of 443 patients. Ann Hematol. 1995;70:79-82.

• 摘要

4.  Schubauer-Berigan MK, Daniels RD, Fleming DA, et al. Risk of chronic myeloid and acute leukemia mortality after exposure to ionizing radiation among workers at four US nuclear weapons facilities and a nuclear naval shipyard. Radiat Res. 2007;167:222-232.

• 摘要

5.  O'Brien S, Berman E, Bhalla K, et al; National Comprehensive Cancer Network. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007;5:474-496.

• 摘要

6.  Hamerschlak N. Leukemia: genetics and prognostic factors. J Pediatr (Rio J). 2008;84(suppl 4):S52-S57.

• 全文
• 摘要

7.  National Institute for Health and Care Excellence. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance. January 2012. http://www.nice.org.uk (last accessed 30 March 2016).

• 全文

8.  Derderian PM, Kantarjian HM, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 1993;94:69-74.

• 摘要

9.  Saglio GH, Cortes JP. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116:3852-3861.

• 摘要

10.  Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007:371-375.

• 全文
• 摘要

11.  Breccia M, Salaroli A, Molica M, et al. Systematic review of dasatinib in chronic myeloid leukemia. Onco Targets Ther. 2013;6:257-265.

• 全文
• 摘要

12.  Shamroe CL, Comeau JM. Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother. 2013;47:1540-1546.

• 摘要

13.  Stansfield L, Hughes TE, Walsh-Chocolaad TL. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia. Ann Pharmacother. 2013;47:1703-1711.

• 摘要

14.  Medicines and Healthcare products Regulatory Agency. Ponatinib (Iclusig): risk of vascular occlusive events - updated advice on possible dose reduction. April 2017. https://www.gov.uk/drug-safety-update/ponatinib-iclusig-risk-of-vascular-occlusive-events-updated-advice-on-possible-dose-reduction (last accessed 25 April 2017).

• 全文

15.  Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA. 2005;102:11011-11016.

• 全文
• 摘要

16.  Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-3475.

• 全文
• 摘要

17.  Kurbegov D, Giralt S. Chapter 9. Allogeneic transplantation. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson manual of medical oncology. New York, NY: McGraw-Hill; 2006:197-218.

18.  Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93.

• 全文
• 摘要